Bayer AG (BAYGn.DE) is under increasing pressure from its shareholders to quicken its turnaround efforts following a dramatic 14.5% drop in share value earlier this week. The German agriculture and pharmaceutical giant has seen its stock hit a 20-year low after warning of weaker farmer demand impacting earnings for 2025.
CEO Bill Anderson, who has been implementing restructuring measures since his appointment, is being urged to deliver tangible results to restore shareholder confidence and reverse the company’s downward trajectory.
Challenges Facing Bayer
- Weak Market Conditions: A slump in farmer incomes, exacerbated by broader agricultural trends, has hit Bayer and competitors like BASF and Corteva.
- Specific Setbacks: Bayer faces unique challenges, including delays in U.S. regulatory approval for a new generation of soy seeds, expected to dent 2025 earnings.
- Monsanto Aftermath: The $63 billion acquisition of Monsanto in 2018 continues to weigh on Bayer through debt and ongoing U.S. litigation over claims that Monsanto’s Roundup weedkiller causes cancer.
- Pharma Struggles: While new drugs like Nubeqa (prostate cancer) and Kerendia (kidney disease) show promise, bestselling blood thinner Xarelto is declining due to patent expiration.
Shareholders Demand Action
Cost Cutting and Efficiency
- CEO Anderson’s efforts include cutting managerial roles, streamlining decision-making, and reducing bureaucracy.
- Shareholders, including Deka Investment and Union Investment, say these changes have not yet significantly impacted revenue or costs.
Pipeline Strengthening
- Investors like Union Investment’s Markus Manns emphasize the need for a stronger pharmaceutical pipeline and clearer long-term growth strategies.
Market Performance and Valuation
- Bayer’s warning of declining earnings contrasts with previous analyst expectations of a 3% increase in adjusted earnings by 2025.
- Despite an attractive valuation at 3.9 times estimated forward earnings (compared to BASF at 11.5 and Corteva at 18.7), analysts at BMO Capital Markets hesitate to recommend the stock due to contracting earnings.
CEO’s Vision and Investor Sentiment
Anderson has pledged to contain litigation risks and improve operational performance. However, shareholder patience is wearing thin. Ingo Speich from Deka warned that without results, management would face increased scrutiny.
While Bayer struggles to project when earnings will bottom out, Anderson remains optimistic about the company’s “bright future.” However, turning this vision into reality will require significant progress in both pharmaceuticals and agricultural products.